Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life
ObjectiveThe aim of this study was to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and to assess the impact of maternal IBD medication use on these outcomes.DesignWe performed a multicentre retrospective study in The Netherlands. Women with...
Gespeichert in:
| Veröffentlicht in: | Gut 2021-07, Vol.70 (7), p.1266-1274 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1274 |
|---|---|
| container_issue | 7 |
| container_start_page | 1266 |
| container_title | Gut |
| container_volume | 70 |
| creator | Kanis, Shannon Linda Modderman, Sanne Escher, Johanna C Erler, Nicole Beukers, Ruud de Boer, Nanne Bodelier, Alexander Depla, Annekatrien C T.M Dijkstra, Gerard van Dijk, Anne-Baue Ruth Margaretha Gilissen, Lennard Hoentjen, Frank Jansen, Jeroen M Kuyvenhoven, Johan Mahmmod, Nofel Mallant-Hent, Rosalie C van der Meulen-de Jong, Andrea E Noruzi, Anahita Oldenburg, Bas Oostenbrug, Liekele E Ter Borg, Pieter C.J. Pierik, Marieke Romberg- Camps, Mariëlle Thijs, Willem West, Rachel de Lima, Alison van der Woude, C Janneke |
| description | ObjectiveThe aim of this study was to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and to assess the impact of maternal IBD medication use on these outcomes.DesignWe performed a multicentre retrospective study in The Netherlands. Women with IBD who gave birth between 1999 and 2018 were enrolled from 20 participating hospitals. Information regarding disease characteristics, medication use, lifestyle, pregnancy outcomes and long-term health outcomes of children was retrieved from mothers and medical charts. After consent of both parents, outcomes until 5 years were also collected from general practitioners. Our primary aim was to assess infection rate and our secondary aims were to assess adverse reactions to vaccinations, growth, autoimmune diseases and malignancies.ResultsWe included 1000 children born to 626 mothers (381 (61%) Crohn’s disease, 225 (36%) ulcerative colitis and 20 (3%) IBD unclassified). In total, 196 (20%) had intrauterine exposure to anti-tumour necrosis factor-α (anti-TNF-α) (60 with concomitant thiopurine) and 240 (24%) were exposed to thiopurine monotherapy. The 564 children (56%) not exposed to anti-TNF-α and/or thiopurine served as control group. There was no association between adverse long-term health outcomes and in utero exposure to IBD treatment. We did find an increased rate of intrahepatic cholestasis of pregnancy (ICP) in case thiopurine was used during the pregnancy without affecting birth outcomes and long-term health outcomes of children. All outcomes correspond with the general age-adjusted population.ConclusionIn our study, we found no association between in utero exposure to anti-TNF-α and/or thiopurine and the long-term outcomes antibiotic-treated infections, severe infections needing hospital admission, adverse reactions to vaccinations, growth failure, autoimmune diseases and malignancies. |
| doi_str_mv | 10.1136/gutjnl-2019-319129 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8223671</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2537905123</sourcerecordid><originalsourceid>FETCH-LOGICAL-b507t-23207fe3c9fc88a6370f3fc4a22bcce28533ba107d1f4a5eecd3f4c476209fd23</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhi0EokvLH-CALHHhkuKPOHYuSKgCilSJCz1bjjPueuXExXao9t_jNu1SOKCe5jDP-2hGL0JvKDmllHcfrpaym0PDCO0bTnvK-mdoQ9tONZwp9RxtCKGyEbLtj9CrnHeEEKV6-hIdcU7aTgi1QfEcTChbHJdi4wQZR4dpBbHd-jAmmPEQ04xLxFMsW0gZ3_iK-9kFM02mxLSvxA0EPPoMJkNd4Qr6hJ1PuWCB92DSnTd4ByfohTMhw-v7eYwuv3z-cXbeXHz_-u3s00UzCCJLwzgj0gG3vbNKmY5L4rizrWFssBaYEpwPhhI5UtcaAWBH7lrbyo6R3o2MH6OPq_d6GSYYLcwlmaCvk59M2utovP57M_utvoq_tGKMd5JWwft7QYo_F8hFTz5bCMHMEJesWStIJwmjfUXf_YPu4pLm-p5mgsueCMp4pdhK2RRzTuAOx1Cib_vUa5_6tk-99llDbx-_cYg8FFiBZgWGafc04ekf_nDmfwK_Aecuu34</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2537905123</pqid></control><display><type>article</type><title>Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life</title><source>MEDLINE</source><source>PubMed Central</source><creator>Kanis, Shannon Linda ; Modderman, Sanne ; Escher, Johanna C ; Erler, Nicole ; Beukers, Ruud ; de Boer, Nanne ; Bodelier, Alexander ; Depla, Annekatrien C T.M ; Dijkstra, Gerard ; van Dijk, Anne-Baue Ruth Margaretha ; Gilissen, Lennard ; Hoentjen, Frank ; Jansen, Jeroen M ; Kuyvenhoven, Johan ; Mahmmod, Nofel ; Mallant-Hent, Rosalie C ; van der Meulen-de Jong, Andrea E ; Noruzi, Anahita ; Oldenburg, Bas ; Oostenbrug, Liekele E ; Ter Borg, Pieter C.J. ; Pierik, Marieke ; Romberg- Camps, Mariëlle ; Thijs, Willem ; West, Rachel ; de Lima, Alison ; van der Woude, C Janneke</creator><creatorcontrib>Kanis, Shannon Linda ; Modderman, Sanne ; Escher, Johanna C ; Erler, Nicole ; Beukers, Ruud ; de Boer, Nanne ; Bodelier, Alexander ; Depla, Annekatrien C T.M ; Dijkstra, Gerard ; van Dijk, Anne-Baue Ruth Margaretha ; Gilissen, Lennard ; Hoentjen, Frank ; Jansen, Jeroen M ; Kuyvenhoven, Johan ; Mahmmod, Nofel ; Mallant-Hent, Rosalie C ; van der Meulen-de Jong, Andrea E ; Noruzi, Anahita ; Oldenburg, Bas ; Oostenbrug, Liekele E ; Ter Borg, Pieter C.J. ; Pierik, Marieke ; Romberg- Camps, Mariëlle ; Thijs, Willem ; West, Rachel ; de Lima, Alison ; van der Woude, C Janneke ; Initiative on Crohns and Colitis (ICC)</creatorcontrib><description>ObjectiveThe aim of this study was to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and to assess the impact of maternal IBD medication use on these outcomes.DesignWe performed a multicentre retrospective study in The Netherlands. Women with IBD who gave birth between 1999 and 2018 were enrolled from 20 participating hospitals. Information regarding disease characteristics, medication use, lifestyle, pregnancy outcomes and long-term health outcomes of children was retrieved from mothers and medical charts. After consent of both parents, outcomes until 5 years were also collected from general practitioners. Our primary aim was to assess infection rate and our secondary aims were to assess adverse reactions to vaccinations, growth, autoimmune diseases and malignancies.ResultsWe included 1000 children born to 626 mothers (381 (61%) Crohn’s disease, 225 (36%) ulcerative colitis and 20 (3%) IBD unclassified). In total, 196 (20%) had intrauterine exposure to anti-tumour necrosis factor-α (anti-TNF-α) (60 with concomitant thiopurine) and 240 (24%) were exposed to thiopurine monotherapy. The 564 children (56%) not exposed to anti-TNF-α and/or thiopurine served as control group. There was no association between adverse long-term health outcomes and in utero exposure to IBD treatment. We did find an increased rate of intrahepatic cholestasis of pregnancy (ICP) in case thiopurine was used during the pregnancy without affecting birth outcomes and long-term health outcomes of children. All outcomes correspond with the general age-adjusted population.ConclusionIn our study, we found no association between in utero exposure to anti-TNF-α and/or thiopurine and the long-term outcomes antibiotic-treated infections, severe infections needing hospital admission, adverse reactions to vaccinations, growth failure, autoimmune diseases and malignancies.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>DOI: 10.1136/gutjnl-2019-319129</identifier><identifier>PMID: 33046558</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and British Society of Gastroenterology</publisher><subject>Adalimumab - therapeutic use ; Adult ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Autoimmune diseases ; Autoimmune Diseases - epidemiology ; azathioprine ; Birth ; Birth weight ; Breastfeeding & lactation ; Cesarean Section - statistics & numerical data ; Child Development - physiology ; Child, Preschool ; Children ; Cholestasis ; Congenital Abnormalities - epidemiology ; Congenital diseases ; Crohn's disease ; Drug Prescriptions - statistics & numerical data ; Drug Therapy, Combination ; Female ; Gallbladder diseases ; Gastroenterology ; Gastrointestinal Agents - therapeutic use ; Gestational age ; Hospitals ; Humans ; Infant ; Infant, Newborn ; Infant, Small for Gestational Age ; Infections ; Infections - drug therapy ; Infections - epidemiology ; Inflammatory Bowel Disease ; Inflammatory bowel diseases ; Inflammatory Bowel Diseases - drug therapy ; infliximab ; Infliximab - therapeutic use ; Intestine ; Intrauterine exposure ; Mercaptopurine - analogs & derivatives ; Mercaptopurine - therapeutic use ; Monoclonal antibodies ; Mothers ; Neoplasms - epidemiology ; Netherlands - epidemiology ; non-steroidal anti-inflammatory drugs ; Obstetrics ; Patient Admission - statistics & numerical data ; Population studies ; Pregnancy ; Pregnancy Complications - epidemiology ; Premature birth ; Premature Birth - epidemiology ; Prenatal Exposure Delayed Effects - epidemiology ; Retrospective Studies ; Side effects ; TNF inhibitors ; Tumor Necrosis Factor Inhibitors - therapeutic use ; Tumor necrosis factor-α ; Tumors ; Ulcerative colitis ; Vaccines - adverse effects ; Variables ; Womens health</subject><ispartof>Gut, 2021-07, Vol.70 (7), p.1266-1274</ispartof><rights>Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b507t-23207fe3c9fc88a6370f3fc4a22bcce28533ba107d1f4a5eecd3f4c476209fd23</citedby><cites>FETCH-LOGICAL-b507t-23207fe3c9fc88a6370f3fc4a22bcce28533ba107d1f4a5eecd3f4c476209fd23</cites><orcidid>0000-0002-2004-7012 ; 0000-0001-8754-9722 ; 0000-0002-4490-6635 ; 0000-0001-6981-6516 ; 0000-0003-4563-7462</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223671/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223671/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33046558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kanis, Shannon Linda</creatorcontrib><creatorcontrib>Modderman, Sanne</creatorcontrib><creatorcontrib>Escher, Johanna C</creatorcontrib><creatorcontrib>Erler, Nicole</creatorcontrib><creatorcontrib>Beukers, Ruud</creatorcontrib><creatorcontrib>de Boer, Nanne</creatorcontrib><creatorcontrib>Bodelier, Alexander</creatorcontrib><creatorcontrib>Depla, Annekatrien C T.M</creatorcontrib><creatorcontrib>Dijkstra, Gerard</creatorcontrib><creatorcontrib>van Dijk, Anne-Baue Ruth Margaretha</creatorcontrib><creatorcontrib>Gilissen, Lennard</creatorcontrib><creatorcontrib>Hoentjen, Frank</creatorcontrib><creatorcontrib>Jansen, Jeroen M</creatorcontrib><creatorcontrib>Kuyvenhoven, Johan</creatorcontrib><creatorcontrib>Mahmmod, Nofel</creatorcontrib><creatorcontrib>Mallant-Hent, Rosalie C</creatorcontrib><creatorcontrib>van der Meulen-de Jong, Andrea E</creatorcontrib><creatorcontrib>Noruzi, Anahita</creatorcontrib><creatorcontrib>Oldenburg, Bas</creatorcontrib><creatorcontrib>Oostenbrug, Liekele E</creatorcontrib><creatorcontrib>Ter Borg, Pieter C.J.</creatorcontrib><creatorcontrib>Pierik, Marieke</creatorcontrib><creatorcontrib>Romberg- Camps, Mariëlle</creatorcontrib><creatorcontrib>Thijs, Willem</creatorcontrib><creatorcontrib>West, Rachel</creatorcontrib><creatorcontrib>de Lima, Alison</creatorcontrib><creatorcontrib>van der Woude, C Janneke</creatorcontrib><creatorcontrib>Initiative on Crohns and Colitis (ICC)</creatorcontrib><title>Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life</title><title>Gut</title><addtitle>Gut</addtitle><addtitle>Gut</addtitle><description>ObjectiveThe aim of this study was to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and to assess the impact of maternal IBD medication use on these outcomes.DesignWe performed a multicentre retrospective study in The Netherlands. Women with IBD who gave birth between 1999 and 2018 were enrolled from 20 participating hospitals. Information regarding disease characteristics, medication use, lifestyle, pregnancy outcomes and long-term health outcomes of children was retrieved from mothers and medical charts. After consent of both parents, outcomes until 5 years were also collected from general practitioners. Our primary aim was to assess infection rate and our secondary aims were to assess adverse reactions to vaccinations, growth, autoimmune diseases and malignancies.ResultsWe included 1000 children born to 626 mothers (381 (61%) Crohn’s disease, 225 (36%) ulcerative colitis and 20 (3%) IBD unclassified). In total, 196 (20%) had intrauterine exposure to anti-tumour necrosis factor-α (anti-TNF-α) (60 with concomitant thiopurine) and 240 (24%) were exposed to thiopurine monotherapy. The 564 children (56%) not exposed to anti-TNF-α and/or thiopurine served as control group. There was no association between adverse long-term health outcomes and in utero exposure to IBD treatment. We did find an increased rate of intrahepatic cholestasis of pregnancy (ICP) in case thiopurine was used during the pregnancy without affecting birth outcomes and long-term health outcomes of children. All outcomes correspond with the general age-adjusted population.ConclusionIn our study, we found no association between in utero exposure to anti-TNF-α and/or thiopurine and the long-term outcomes antibiotic-treated infections, severe infections needing hospital admission, adverse reactions to vaccinations, growth failure, autoimmune diseases and malignancies.</description><subject>Adalimumab - therapeutic use</subject><subject>Adult</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Autoimmune diseases</subject><subject>Autoimmune Diseases - epidemiology</subject><subject>azathioprine</subject><subject>Birth</subject><subject>Birth weight</subject><subject>Breastfeeding & lactation</subject><subject>Cesarean Section - statistics & numerical data</subject><subject>Child Development - physiology</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Cholestasis</subject><subject>Congenital Abnormalities - epidemiology</subject><subject>Congenital diseases</subject><subject>Crohn's disease</subject><subject>Drug Prescriptions - statistics & numerical data</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Gallbladder diseases</subject><subject>Gastroenterology</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Gestational age</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Infant, Small for Gestational Age</subject><subject>Infections</subject><subject>Infections - drug therapy</subject><subject>Infections - epidemiology</subject><subject>Inflammatory Bowel Disease</subject><subject>Inflammatory bowel diseases</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>infliximab</subject><subject>Infliximab - therapeutic use</subject><subject>Intestine</subject><subject>Intrauterine exposure</subject><subject>Mercaptopurine - analogs & derivatives</subject><subject>Mercaptopurine - therapeutic use</subject><subject>Monoclonal antibodies</subject><subject>Mothers</subject><subject>Neoplasms - epidemiology</subject><subject>Netherlands - epidemiology</subject><subject>non-steroidal anti-inflammatory drugs</subject><subject>Obstetrics</subject><subject>Patient Admission - statistics & numerical data</subject><subject>Population studies</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - epidemiology</subject><subject>Premature birth</subject><subject>Premature Birth - epidemiology</subject><subject>Prenatal Exposure Delayed Effects - epidemiology</subject><subject>Retrospective Studies</subject><subject>Side effects</subject><subject>TNF inhibitors</subject><subject>Tumor Necrosis Factor Inhibitors - therapeutic use</subject><subject>Tumor necrosis factor-α</subject><subject>Tumors</subject><subject>Ulcerative colitis</subject><subject>Vaccines - adverse effects</subject><subject>Variables</subject><subject>Womens health</subject><issn>0017-5749</issn><issn>1468-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkU1v1DAQhi0EokvLH-CALHHhkuKPOHYuSKgCilSJCz1bjjPueuXExXao9t_jNu1SOKCe5jDP-2hGL0JvKDmllHcfrpaym0PDCO0bTnvK-mdoQ9tONZwp9RxtCKGyEbLtj9CrnHeEEKV6-hIdcU7aTgi1QfEcTChbHJdi4wQZR4dpBbHd-jAmmPEQ04xLxFMsW0gZ3_iK-9kFM02mxLSvxA0EPPoMJkNd4Qr6hJ1PuWCB92DSnTd4ByfohTMhw-v7eYwuv3z-cXbeXHz_-u3s00UzCCJLwzgj0gG3vbNKmY5L4rizrWFssBaYEpwPhhI5UtcaAWBH7lrbyo6R3o2MH6OPq_d6GSYYLcwlmaCvk59M2utovP57M_utvoq_tGKMd5JWwft7QYo_F8hFTz5bCMHMEJesWStIJwmjfUXf_YPu4pLm-p5mgsueCMp4pdhK2RRzTuAOx1Cib_vUa5_6tk-99llDbx-_cYg8FFiBZgWGafc04ekf_nDmfwK_Aecuu34</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Kanis, Shannon Linda</creator><creator>Modderman, Sanne</creator><creator>Escher, Johanna C</creator><creator>Erler, Nicole</creator><creator>Beukers, Ruud</creator><creator>de Boer, Nanne</creator><creator>Bodelier, Alexander</creator><creator>Depla, Annekatrien C T.M</creator><creator>Dijkstra, Gerard</creator><creator>van Dijk, Anne-Baue Ruth Margaretha</creator><creator>Gilissen, Lennard</creator><creator>Hoentjen, Frank</creator><creator>Jansen, Jeroen M</creator><creator>Kuyvenhoven, Johan</creator><creator>Mahmmod, Nofel</creator><creator>Mallant-Hent, Rosalie C</creator><creator>van der Meulen-de Jong, Andrea E</creator><creator>Noruzi, Anahita</creator><creator>Oldenburg, Bas</creator><creator>Oostenbrug, Liekele E</creator><creator>Ter Borg, Pieter C.J.</creator><creator>Pierik, Marieke</creator><creator>Romberg- Camps, Mariëlle</creator><creator>Thijs, Willem</creator><creator>West, Rachel</creator><creator>de Lima, Alison</creator><creator>van der Woude, C Janneke</creator><general>BMJ Publishing Group Ltd and British Society of Gastroenterology</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2004-7012</orcidid><orcidid>https://orcid.org/0000-0001-8754-9722</orcidid><orcidid>https://orcid.org/0000-0002-4490-6635</orcidid><orcidid>https://orcid.org/0000-0001-6981-6516</orcidid><orcidid>https://orcid.org/0000-0003-4563-7462</orcidid></search><sort><creationdate>20210701</creationdate><title>Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life</title><author>Kanis, Shannon Linda ; Modderman, Sanne ; Escher, Johanna C ; Erler, Nicole ; Beukers, Ruud ; de Boer, Nanne ; Bodelier, Alexander ; Depla, Annekatrien C T.M ; Dijkstra, Gerard ; van Dijk, Anne-Baue Ruth Margaretha ; Gilissen, Lennard ; Hoentjen, Frank ; Jansen, Jeroen M ; Kuyvenhoven, Johan ; Mahmmod, Nofel ; Mallant-Hent, Rosalie C ; van der Meulen-de Jong, Andrea E ; Noruzi, Anahita ; Oldenburg, Bas ; Oostenbrug, Liekele E ; Ter Borg, Pieter C.J. ; Pierik, Marieke ; Romberg- Camps, Mariëlle ; Thijs, Willem ; West, Rachel ; de Lima, Alison ; van der Woude, C Janneke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b507t-23207fe3c9fc88a6370f3fc4a22bcce28533ba107d1f4a5eecd3f4c476209fd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adalimumab - therapeutic use</topic><topic>Adult</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Autoimmune diseases</topic><topic>Autoimmune Diseases - epidemiology</topic><topic>azathioprine</topic><topic>Birth</topic><topic>Birth weight</topic><topic>Breastfeeding & lactation</topic><topic>Cesarean Section - statistics & numerical data</topic><topic>Child Development - physiology</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Cholestasis</topic><topic>Congenital Abnormalities - epidemiology</topic><topic>Congenital diseases</topic><topic>Crohn's disease</topic><topic>Drug Prescriptions - statistics & numerical data</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Gallbladder diseases</topic><topic>Gastroenterology</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Gestational age</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Infant, Small for Gestational Age</topic><topic>Infections</topic><topic>Infections - drug therapy</topic><topic>Infections - epidemiology</topic><topic>Inflammatory Bowel Disease</topic><topic>Inflammatory bowel diseases</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>infliximab</topic><topic>Infliximab - therapeutic use</topic><topic>Intestine</topic><topic>Intrauterine exposure</topic><topic>Mercaptopurine - analogs & derivatives</topic><topic>Mercaptopurine - therapeutic use</topic><topic>Monoclonal antibodies</topic><topic>Mothers</topic><topic>Neoplasms - epidemiology</topic><topic>Netherlands - epidemiology</topic><topic>non-steroidal anti-inflammatory drugs</topic><topic>Obstetrics</topic><topic>Patient Admission - statistics & numerical data</topic><topic>Population studies</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - epidemiology</topic><topic>Premature birth</topic><topic>Premature Birth - epidemiology</topic><topic>Prenatal Exposure Delayed Effects - epidemiology</topic><topic>Retrospective Studies</topic><topic>Side effects</topic><topic>TNF inhibitors</topic><topic>Tumor Necrosis Factor Inhibitors - therapeutic use</topic><topic>Tumor necrosis factor-α</topic><topic>Tumors</topic><topic>Ulcerative colitis</topic><topic>Vaccines - adverse effects</topic><topic>Variables</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanis, Shannon Linda</creatorcontrib><creatorcontrib>Modderman, Sanne</creatorcontrib><creatorcontrib>Escher, Johanna C</creatorcontrib><creatorcontrib>Erler, Nicole</creatorcontrib><creatorcontrib>Beukers, Ruud</creatorcontrib><creatorcontrib>de Boer, Nanne</creatorcontrib><creatorcontrib>Bodelier, Alexander</creatorcontrib><creatorcontrib>Depla, Annekatrien C T.M</creatorcontrib><creatorcontrib>Dijkstra, Gerard</creatorcontrib><creatorcontrib>van Dijk, Anne-Baue Ruth Margaretha</creatorcontrib><creatorcontrib>Gilissen, Lennard</creatorcontrib><creatorcontrib>Hoentjen, Frank</creatorcontrib><creatorcontrib>Jansen, Jeroen M</creatorcontrib><creatorcontrib>Kuyvenhoven, Johan</creatorcontrib><creatorcontrib>Mahmmod, Nofel</creatorcontrib><creatorcontrib>Mallant-Hent, Rosalie C</creatorcontrib><creatorcontrib>van der Meulen-de Jong, Andrea E</creatorcontrib><creatorcontrib>Noruzi, Anahita</creatorcontrib><creatorcontrib>Oldenburg, Bas</creatorcontrib><creatorcontrib>Oostenbrug, Liekele E</creatorcontrib><creatorcontrib>Ter Borg, Pieter C.J.</creatorcontrib><creatorcontrib>Pierik, Marieke</creatorcontrib><creatorcontrib>Romberg- Camps, Mariëlle</creatorcontrib><creatorcontrib>Thijs, Willem</creatorcontrib><creatorcontrib>West, Rachel</creatorcontrib><creatorcontrib>de Lima, Alison</creatorcontrib><creatorcontrib>van der Woude, C Janneke</creatorcontrib><creatorcontrib>Initiative on Crohns and Colitis (ICC)</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanis, Shannon Linda</au><au>Modderman, Sanne</au><au>Escher, Johanna C</au><au>Erler, Nicole</au><au>Beukers, Ruud</au><au>de Boer, Nanne</au><au>Bodelier, Alexander</au><au>Depla, Annekatrien C T.M</au><au>Dijkstra, Gerard</au><au>van Dijk, Anne-Baue Ruth Margaretha</au><au>Gilissen, Lennard</au><au>Hoentjen, Frank</au><au>Jansen, Jeroen M</au><au>Kuyvenhoven, Johan</au><au>Mahmmod, Nofel</au><au>Mallant-Hent, Rosalie C</au><au>van der Meulen-de Jong, Andrea E</au><au>Noruzi, Anahita</au><au>Oldenburg, Bas</au><au>Oostenbrug, Liekele E</au><au>Ter Borg, Pieter C.J.</au><au>Pierik, Marieke</au><au>Romberg- Camps, Mariëlle</au><au>Thijs, Willem</au><au>West, Rachel</au><au>de Lima, Alison</au><au>van der Woude, C Janneke</au><aucorp>Initiative on Crohns and Colitis (ICC)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life</atitle><jtitle>Gut</jtitle><stitle>Gut</stitle><addtitle>Gut</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>70</volume><issue>7</issue><spage>1266</spage><epage>1274</epage><pages>1266-1274</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><abstract>ObjectiveThe aim of this study was to describe the long-term health outcomes of children born to mothers with inflammatory bowel disease (IBD) and to assess the impact of maternal IBD medication use on these outcomes.DesignWe performed a multicentre retrospective study in The Netherlands. Women with IBD who gave birth between 1999 and 2018 were enrolled from 20 participating hospitals. Information regarding disease characteristics, medication use, lifestyle, pregnancy outcomes and long-term health outcomes of children was retrieved from mothers and medical charts. After consent of both parents, outcomes until 5 years were also collected from general practitioners. Our primary aim was to assess infection rate and our secondary aims were to assess adverse reactions to vaccinations, growth, autoimmune diseases and malignancies.ResultsWe included 1000 children born to 626 mothers (381 (61%) Crohn’s disease, 225 (36%) ulcerative colitis and 20 (3%) IBD unclassified). In total, 196 (20%) had intrauterine exposure to anti-tumour necrosis factor-α (anti-TNF-α) (60 with concomitant thiopurine) and 240 (24%) were exposed to thiopurine monotherapy. The 564 children (56%) not exposed to anti-TNF-α and/or thiopurine served as control group. There was no association between adverse long-term health outcomes and in utero exposure to IBD treatment. We did find an increased rate of intrahepatic cholestasis of pregnancy (ICP) in case thiopurine was used during the pregnancy without affecting birth outcomes and long-term health outcomes of children. All outcomes correspond with the general age-adjusted population.ConclusionIn our study, we found no association between in utero exposure to anti-TNF-α and/or thiopurine and the long-term outcomes antibiotic-treated infections, severe infections needing hospital admission, adverse reactions to vaccinations, growth failure, autoimmune diseases and malignancies.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and British Society of Gastroenterology</pub><pmid>33046558</pmid><doi>10.1136/gutjnl-2019-319129</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-2004-7012</orcidid><orcidid>https://orcid.org/0000-0001-8754-9722</orcidid><orcidid>https://orcid.org/0000-0002-4490-6635</orcidid><orcidid>https://orcid.org/0000-0001-6981-6516</orcidid><orcidid>https://orcid.org/0000-0003-4563-7462</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0017-5749 |
| ispartof | Gut, 2021-07, Vol.70 (7), p.1266-1274 |
| issn | 0017-5749 1468-3288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8223671 |
| source | MEDLINE; PubMed Central |
| subjects | Adalimumab - therapeutic use Adult Anti-Bacterial Agents - therapeutic use Antibiotics Autoimmune diseases Autoimmune Diseases - epidemiology azathioprine Birth Birth weight Breastfeeding & lactation Cesarean Section - statistics & numerical data Child Development - physiology Child, Preschool Children Cholestasis Congenital Abnormalities - epidemiology Congenital diseases Crohn's disease Drug Prescriptions - statistics & numerical data Drug Therapy, Combination Female Gallbladder diseases Gastroenterology Gastrointestinal Agents - therapeutic use Gestational age Hospitals Humans Infant Infant, Newborn Infant, Small for Gestational Age Infections Infections - drug therapy Infections - epidemiology Inflammatory Bowel Disease Inflammatory bowel diseases Inflammatory Bowel Diseases - drug therapy infliximab Infliximab - therapeutic use Intestine Intrauterine exposure Mercaptopurine - analogs & derivatives Mercaptopurine - therapeutic use Monoclonal antibodies Mothers Neoplasms - epidemiology Netherlands - epidemiology non-steroidal anti-inflammatory drugs Obstetrics Patient Admission - statistics & numerical data Population studies Pregnancy Pregnancy Complications - epidemiology Premature birth Premature Birth - epidemiology Prenatal Exposure Delayed Effects - epidemiology Retrospective Studies Side effects TNF inhibitors Tumor Necrosis Factor Inhibitors - therapeutic use Tumor necrosis factor-α Tumors Ulcerative colitis Vaccines - adverse effects Variables Womens health |
| title | Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A56%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Health%20outcomes%20of%201000%20children%20born%20to%20mothers%20with%20inflammatory%20bowel%20disease%20in%20their%20first%205%20years%20of%20life&rft.jtitle=Gut&rft.au=Kanis,%20Shannon%20Linda&rft.aucorp=Initiative%20on%20Crohns%20and%20Colitis%20(ICC)&rft.date=2021-07-01&rft.volume=70&rft.issue=7&rft.spage=1266&rft.epage=1274&rft.pages=1266-1274&rft.issn=0017-5749&rft.eissn=1468-3288&rft_id=info:doi/10.1136/gutjnl-2019-319129&rft_dat=%3Cproquest_pubme%3E2537905123%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2537905123&rft_id=info:pmid/33046558&rfr_iscdi=true |